News Sanofi to lay off 229 Blueprint employees, close offices A year after its $9.1bn acquisition of Blueprint Medicines, Sanofi is moving out of Blueprint's Cambridge, MA offices and letting 229 employees go.
News Sanofi drops two more programmes in R&D clear-out Shortly after terminating one late-stage R&D programme, Sanofi confirmed in its second-quarter update that two others are being scrapped.
News Sanofi gives up on amlitelimab in atopic dermatitis Sanofi has stopped development of anti-OX40L drug amlitelimab in atopic dermatitis, a major blow to what was once viewed as a 'pipeline-in-a-product'.
News EU seeks advice on Sanofi's response to mismarketing claim The EU is asking for feedback on measures proposed by Sanofi to address concerns about an allegedly misleading marketing campaign for a flu vaccine.
News Sanofi eyes extending Nexviazyme into infantile Pompe Armed with new phase 3 data, Sanofi will try to expand the US label of its Pompe disease drug Nexviazyme to include the severe infantile-onset form.
News Sanofi's type 1 diabetes-delaying drug cleared for NHS use People with early type 1 diabetes in England and Wales will soon be able to access Sanofi's Tzield, which can delay the need for insulin injections.
News Isomorphic Labs raises $5bn in massive third round In yet another sign of the appetite for AI companies among investors, Isomorphic Labs has raised a whopping $5bn in a Series C financing.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.